(Q81573779)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16327841%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

title

Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16327841%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

main subject

acute myeloid leukemia

1 reference

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16327841%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

John Carstensen

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16327841%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Erik Holmberg

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16327841%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

author name string

G Juliusson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16327841%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

R Billström

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16327841%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

A Gruber

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16327841%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

E Hellström-Lindberg

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16327841%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

M Höglunds

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16327841%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

K Karlsson

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16327841%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

D Stockelberg

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16327841%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

A Wahlin

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16327841%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

C Arnesson

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16327841%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

U Brunell-Abrahamsson

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16327841%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

E Fredriksson

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16327841%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

K Nordenskjöld

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16327841%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

F Wiklund

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16327841%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Swedish Adult Acute Leukemia Registry Group

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16327841%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

publication date

1 January 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16327841%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16327841%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16327841%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16327841%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

page(s)

42-47

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16327841%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404004

10 January 2020

exact match

0 references

cites work

Management of acute myeloid leukemia in elderly patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404004

7 January 2021

Acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404004

7 January 2021

High-dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparison

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404004

7 January 2021

On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404004

7 January 2021

Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404004

7 January 2021

Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404004

7 January 2021

Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404004

7 January 2021

Treatment of newly-diagnosed acute myelogenous leukaemia in patients aged 80 years and above

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404004

7 January 2021

Acute myeloid leukemia in the elderly: a critical review of therapeutic approaches and appraisal of results of therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404004

7 January 2021

Acute myeloid leukemia in elderly patients aged over 75 years: experience of a single centre.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404004

7 January 2021

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404004

7 January 2021

The difficult problem of acute myeloid leukemia in the older adult

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404004

7 January 2021

Assessment of differences in patient populations selected for excluded from participation in clinical phase III acute myelogenous leukemia trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404004

7 January 2021

Adjustment of incidence rates after an estimate of completeness and accuracy in registration of acute leukemias in a Swedish population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404004

7 January 2021

Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404004

7 January 2021

A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404004

7 January 2021

A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404004

7 January 2021

Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404004

7 January 2021